Media Contact: Lissa Pavluk media@apellis.com (617) 977-6764 Year All202520242023202220212020201920182017201620152014 June 23, 2016 Apellis Announces Positive Results from Phase 1 Clinical Trials of APL-2, a C3 Complement Inhibitor July 15, 2015 Apellis Pharmaceuticals Announces Formation of Scientific Advisory Board February 10, 2015 Apellis Pharmaceuticals Enters Clinical Testing Phase in its Age-Related Macular Degeneration Program December 2, 2014 Apellis Pharmaceuticals Raises $33M to Fund its Complement Immunotherapy Programs November 20, 2014 Apellis Pharmaceuticals to acquire Potentia Pharmaceuticals.